Arbutus, Genevant sue Moderna over COVID-19 vaccine tech
01-03-2022
Moderna’s COVID-19 and Zika patent applications to be investigated
08-09-2020
Moderna unsure of COVID-19 vaccine patent exclusivity
12-08-2020
isak55 / shutterstock.com
Biotech company Moderna has failed to have a US patent owned by its competitor Arbutus Biopharma revoked, following a decision handed down by the Patent Trial and Appeal Board (PTAB) yesterday, July 23.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Moderna, Arbutus, PTAB, Biopharma, patent, USPTO, COVID-19, LNP technology, IP, board, PTAB, vaccines, Appeals
